KI
Kilitch Drugs (India) Ltd (KILITCH)
₹221.00
Mkt cap
₹790 Cr
P/E ratio
32.80
P/B
2.68
Div yield
0.00%
ROE
10.60%
ROCE
13.40%
EPS (TTM)
₹6.74
Book value
₹83
52W range
117–268
Sector
Healthcare
Price history
Previous close
Incorporated in 1978, Kilitch Drugs Ltd is engaged in the operation and management of Pharmaceutical Products [1]
NSE KILITCHBSE 524500
Health check
Constructive
ValuationFair
ProfitabilityAverage
GrowthHigh
TechnicalsBullish
52-week range
−17.51% from high₹221
₹117+88.49% from low₹268
Current
₹221.00
Prev close
₹236.95
Day
−6.73%
Price performance
1D
−6.73%
1W
+2.74%
1M
+9.35%
3M
+35.97%
6M
+20.73%
1Y
+23.00%
YTD
+22.64%
Financials
Revenue, profit & margin
P/E ratio
32.8×
KILITCH is 1% above the sector median of 32.5×
KILITCH32.8×
Sector median32.5×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41.20 | 31.79 | 44.82 | 33.45 | 47.47 | 56.17 | 61.23 | 43.14 | 48.92 | 53.81 | 89.60 | 44.88 | 50.22 | |
| YoY Sales growth | +34.20% | +6.07% | -1.45% | -8.51% | +15.22% | +76.69% | +36.61% | +28.97% | +3.05% | -4.20% | +46.33% | +4.03% | +2.66% | |
| Expenses | 32.58 | 29.51 | 37.74 | 31.79 | 41.37 | 47.44 | 46.64 | 39.88 | 43.88 | 47.66 | 67.46 | 41.94 | 43.53 | |
| Operating Profit | 8.62 | 2.28 | 7.08 | 1.66 | 6.10 | 8.73 | 14.59 | 3.26 | 5.04 | 6.15 | 22.14 | 2.94 | 6.69 | |
| OPM % | 20.92% | 7.17% | 15.80% | 4.96% | 12.85% | 15.54% | 23.83% | 7.56% | 10.30% | 11.43% | 24.71% | 6.55% | 13.32% | |
| Other Income | 0.49 | 2.96 | 0.47 | 2.57 | 5.16 | 1.73 | 1.70 | 2.56 | 6.66 | 1.53 | 0.49 | 2.90 | 2.16 | |
| Interest | 1.51 | 1.60 | 1.32 | 1.73 | 0.31 | 1.40 | 1.60 | 1.53 | 1.44 | 1.15 | 1.44 | 0.88 | 1.69 | |
| Depreciation | 0.82 | 0.81 | 0.93 | 0.85 | 0.61 | 0.81 | 0.85 | 0.84 | 0.86 | 0.94 | 0.98 | 1.09 | 3.82 | |
| Profit before tax | 6.78 | 2.83 | 5.30 | 1.65 | 10.34 | 8.25 | 13.84 | 3.45 | 9.40 | 5.59 | 20.21 | 3.87 | 3.34 | |
| Tax % | 24.93% | 38.16% | 30.57% | 93.33% | 16.73% | 32.00% | 26.23% | 34.49% | 14.47% | 22.90% | 26.37% | 48.84% | 57.49% | |
| Net Profit | 5.09 | 1.74 | 3.68 | 0.11 | 8.61 | 5.61 | 10.22 | 2.27 | 8.04 | 4.31 | 14.88 | 1.96 | 1.42 | |
| EPS in Rs | 1.44 | 0.88 | 1.09 | 0.41 | 2.62 | 1.81 | 3.16 | 0.92 | 2.34 | 1.27 | 4.15 | 0.83 | 0.64 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202663.77%Promoter
Promoters63.77%
FIIs0.10%0.02
DIIs0.50%0.50
Public35.62%0.49
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,884.90 | 36.70 | 4,51,538 | 0.85% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹11,180.50 | 86.86 | 2,96,807 | 0.27% | 1,127 | +63.57% | 3,676 | +35.40% | 21.97% |
| Torrent Pharma. | ₹4,689.50 | 82.07 | 1,78,180 | 0.81% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,294.60 | 92.69 | 1,24,195 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,200.00 | 26.48 | 1,19,990 | 0.08% | 928 | −27.96% | 7,910 | +29.17% | 21.14% |
| Dr Reddy's Labs | ₹1,390.20 | 41.56 | 1,16,360 | 0.58% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,415.00 | 36.88 | 1,14,518 | 0.92% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Kilitch Drugs | ₹223.81 | 32.80 | 790 | 0.00% | 1 | −72.77% | 50 | +2.66% | 13.43% |
| Median: 160 Co. | ₹432.20 | 32.47 | 1,987 | 0.08% | 13 | +33.73% | 179 | +21.23% | 14.94% |
Filings
Annual reports15
Concall transcripts2
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 16 NovShareholder Meeting / Postal Ballot-Outcome of EGM 16 Nov - EGM on 16 Nov 2026 approved sale of material subsidiary stake, debt-to-equity conversion, and two independent director appointments.Announcement under Regulation 30 (LODR)-Newspaper Publication 15 Nov - Newspaper Publication of Corrigendum to EGM NoticeIntimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015, Corrigendum To The Notice Of Extra Ordinary General Meeting (''EGM Notice''). 12 NovRectification Of Typo Error In The Outcome Of Board Meeting Dated 22Nd October, 2026 12 Nov - Typo rectified in KEB conversion: 1,66,471 shares at INR 3,413.23 each.






